Berger, Marc G.

Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients

Nicolini, F. E., Dulucq, S., Boureau, L., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Rigal-Huguet, F., Coiteux, V., Varet, B., Dubruille, V., et al. (2019) · Clinical Cancer Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 111

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Dulucq, S., Nicolini, F. E., Rea, D., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Coiteux, V., Lenain, P., Rigal-Huguet, F., Liu, J., et al. (2022) · Haematologica

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 17

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Efficace, F., Mahon, F.-X., Richter, J., Piciocchi, A., Cipriani, M., Nicolini, F. E., Mayer, J., Zackova, D., Janssen, J. J. W. M., Panayiotidis, P., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsCancer survivorship and care

Cited by 15

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia

Balsat, M., Alcazer, V., Etienne, G., Huguet, F., Berger, M., Cayssials, E., Charbonnier, A., Escoffre-Barbe, M., Johnson-Ansah, H., Legros, L., et al. (2023) · Leukemia Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 5